{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"50","value":"45.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"203"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"8 mg/kg of ramucirumab (IMC-1121B) was administered by IV infusion on Days 1 and 15 in combination with 80 mg/m² paclitaxel administered by IV infusion on Days 1, 8, and 15 of a 28-day cycle.","id":"OG000","title":"Ramucirumab (IMC-1211B) Plus Paclitaxel"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All participants who received Ramucirumab (IMC-1121B) plus Paclitaxel and had Cmin observations at specific timepoint.","reportingStatus":"POSTED","timeFrame":"Cycle 2, Day 15 (28-day cycle)","title":"Cmin Prior to 4th Ramucirumab (IMC-1211B) Infusion","type":"SECONDARY","unitOfMeasure":"µg/mL"}